These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37061369)

  • 1. Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.
    Khanam F; Babu G; Rahman N; Liu X; Rajib NH; Ahmed SU; Hossen MI; Biswas PK; Kelly S; Thesis-Nyland K; Mujadidi Y; McMillan NAJ; Pollard AJ; Clemens JD; Qadri F
    Vaccine; 2023 May; 41(19):3137-3140. PubMed ID: 37061369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
    Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD
    Lancet; 2021 Aug; 398(10301):675-684. PubMed ID: 34384540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination.
    Vadrevu KM; Raju D; Rani S; Reddy S; Sarangi V; Ella R; Javvaji B; Mahantshetty NS; Battu S; Levine MM
    Vaccine; 2021 Oct; 39(45):6682-6690. PubMed ID: 34625288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
    Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
    Jin C; Gibani MM; Moore M; Juel HB; Jones E; Meiring J; Harris V; Gardner J; Nebykova A; Kerridge SA; Hill J; Thomaides-Brears H; Blohmke CJ; Yu LM; Angus B; Pollard AJ
    Lancet; 2017 Dec; 390(10111):2472-2480. PubMed ID: 28965718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
    Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
    Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgA and IgG1 Specific to Vi Polysaccharide of
    Dahora LC; Jin C; Spreng RL; Feely F; Mathura R; Seaton KE; Zhang L; Hill J; Jones E; Alam SM; Dennison SM; Pollard AJ; Tomaras GD
    Front Immunol; 2019; 10():2582. PubMed ID: 31781100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.
    Cross DL; Verheul MK; Leipold MD; Obermoser G; Jin C; Jones E; Starr JS; Mohorianu I; Blohmke CJ; Maecker HT; Napolitani G; Hill J; Pollard AJ
    Front Immunol; 2020; 11():574057. PubMed ID: 33424833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
    Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal.
    Chaudhary S; Shah GS; Bhatta NK; Poudel P; Rai B; Uranw S; Tripathi PM; Khanal B; Ghimire A; Rai N; Gupta BP; Vemula S; Wartel TA; Sahastrabuddhe S; Saluja T
    Hum Vaccin Immunother; 2023 Dec; 19(1):2203634. PubMed ID: 37128723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).
    Voysey M; Pollard AJ
    Clin Infect Dis; 2018 Jun; 67(1):18-24. PubMed ID: 29351594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT).
    Lee EY; Park JY; Kim DR; Song M; Sahastrabuddhe S; Kim H; Chon Y; Yang JS
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008171. PubMed ID: 32203521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
    Szu SC; Klugman KP; Hunt S
    Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses.
    Jossi SE; Arcuri M; Alshayea A; Persaud RR; Marcial-Juárez E; Palmieri E; Di Benedetto R; Pérez-Toledo M; Pillaye J; Channell WM; Schager AE; Lamerton RE; Cook CN; Goodall M; Haneda T; Bäumler AJ; Jackson-Jones LH; Toellner KM; MacLennan CA; Henderson IR; Micoli F; Cunningham AF
    Front Immunol; 2023; 14():1139329. PubMed ID: 37033932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIIb Trial.
    Theiss-Nyland K; Qadri F; Colin-Jones R; Zaman K; Khanam F; Liu X; Voysey M; Khan A; Hasan N; Ashher F; Farooq YG; Pollard AJ; Clemens JD
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S74-S82. PubMed ID: 30845333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of Typhoid by Vi Conjugate Vaccine and Achievable Improvements in Household Water, Sanitation, and Hygiene: Evidence From a Cluster-Randomized Trial in Dhaka, Bangladesh.
    Tadesse BT; Khanam F; Ahmmed F; Im J; Islam MT; Kim DR; Kang SSY; Liu X; Chowdhury F; Ahmed T; Binte Aziz A; Hoque M; Park J; Pak G; Zaman K; Khan AI; Pollard AJ; Kim JH; Marks F; Qadri F; Clemens JD
    Clin Infect Dis; 2022 Nov; 75(10):1681-1687. PubMed ID: 35412603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of alum-based adjuvant on the immunogenicity of salmonella enterica serovar typhi conjugates vaccines.
    Tritama E; Riani C; Rudiansyah I; Hidayat A; Kharisnaeni SA; Retnoningrum DS
    Hum Vaccin Immunother; 2018 Jun; 14(6):1524-1529. PubMed ID: 29359991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso.
    Ouedraogo A; Diarra A; Nébié I; Barry N; Kabore JM; Tiono AB; Datta S; Liang Y; Mayo I; Oshinsky JJ; Tracy JK; Girmay T; Pasetti MF; Jamka LP; Neuzil KM; Sirima SB; Laurens MB
    J Pediatric Infect Dis Soc; 2023 Sep; 12(9):513-518. PubMed ID: 37589596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11 years: a phase II preliminary report.
    Medise BE; Soedjatmiko S; Gunardi H; Sekartini R; Satari HI; Hadinegoro SR; Wirahmadi A; Puspita M; Sari RM; Yang JS; Sil A; Sahastrabuddhe S; Bachtiar NS
    BMC Pediatr; 2020 Oct; 20(1):480. PubMed ID: 33059607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
    Patel PD; Liang Y; Meiring JE; Chasweka N; Patel P; Misiri T; Mwakiseghile F; Wachepa R; Banda HC; Shumba F; Kawalazira G; Dube Q; Nampota-Nkomba N; Nyirenda OM; Girmay T; Datta S; Jamka LP; Tracy JK; Laurens MB; Heyderman RS; Neuzil KM; Gordon MA;
    Lancet; 2024 Feb; 403(10425):459-468. PubMed ID: 38281499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.